Carmell Ebt Per Ebit from 2010 to 2024

CTCXW Stock   0.06  0  1.96%   
Carmell Therapeutics Ebt Per Ebit yearly trend continues to be fairly stable with very little volatility. Ebt Per Ebit will likely drop to 2.97 in 2024. During the period from 2010 to 2024, Carmell Therapeutics Ebt Per Ebit regression line of quarterly data had mean square error of  0.17 and geometric mean of  3.14. View All Fundamentals
 
Ebt Per Ebit  
First Reported
2010-12-31
Previous Quarter
3.1060729
Current Value
2.97
Quarterly Volatility
0.44027721
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Carmell Therapeutics' Ebt Per Ebit Growth Pattern

Below is the plot of the Ebt Per Ebit of Carmell Therapeutics over the last few years. It is Carmell Therapeutics' Ebt Per Ebit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebt Per Ebit10 Years Trend
Slightly volatile
   Ebt Per Ebit   
       Timeline  

Carmell Ebt Per Ebit Regression Statistics

Arithmetic Mean3.19
Geometric Mean3.14
Coefficient Of Variation13.82
Mean Deviation0.25
Median3.34
Standard Deviation0.44
Sample Variance0.19
Range1.6957
R-Value(0.45)
Mean Square Error0.17
R-Squared0.20
Significance0.09
Slope(0.04)
Total Sum of Squares2.71

Carmell Ebt Per Ebit History

2024 2.97
2023 3.11
2022 1.64

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Ebt Per Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebt Per Ebit 3.11  2.97 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.